The studies will be conducted by Charles River Laboratories, and follows a recently completed 28-day preclinical safety program, also performed by Charles River.
AKP-020 is the product designation for a novel vanadium compound otherwise known as bis(ethylmaltolato)oxovanadium (IV), or BEOV.
Jay Lichter, president and CEO of Akesis, said: “The initial results from the earlier trial are encouraging, and we believe warrant this additional research.”